Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population

Lipids in Health and Disease

Aldo Galluzzo¹  Maria Pitrone¹  Carla Giordano¹  Marco C Amato¹ 

[1] Dipartimento Biomedico di Medicina interna e specialistica (Dibimis), Section of Endocrinology, University of Palermo; Piazza Cliniche 2, 90127 Palermo, Italy

关键词: VAI;    visceral adipose dynsfunction;    cardiometabolic risk;    Obesity;   

Others  :  1212477
DOI  :  10.1186/1476-511X-10-183

 received in 2011-09-12, accepted in 2011-10-19,  发布年份 2011

【 摘 要 】

Background

The Visceral Adiposity Index (VAI) is a sex-specific mathematical index, based on Waist Circumference (WC), Body Mass Index (BMI), triglycerides (TG) and HDL cholesterol (HDL) levels, indirectly expressing visceral adipose function and insulin sensitivity. Our aim was to find the optimal cut-off points of VAI identifying a visceral adipose dysfunction (VAD) associated with cardiometabolic risk in a Caucasian Sicilian population.

Methods

Medical check-up data of 1,764 Primary Care patients (PC patients) were retrospectively and cross-sectionally examined using a receiver-operating characteristic (ROC) curve to determine appropriate stratified-for-age cut-off of VAI, for the identification of PC patients with Metabolic Syndrome (MetS) according to the NCEP-ATP III criteria. The PC patients with higher VAI scores were subdivided into three groups according to VAI tertiles (i.e. PC patients with mild VAD, moderate VAD or severe VAD). Finally, VAD classes were compared to classical cardio- and cerebrovascular risk factors as independent predictors of coronary heart disease and/or myocardial infarction, transient ischemic attack and/or ischemic stroke.

Results

Moderate and severe VADs proved to be independently associated with cardiovascular events [(OR: 5.35; 95% CI: 1.92-14.87; p = 0.001) and (OR: 7.46; 95% CI: 2.64-21.05; p < 0.001) respectively]. Mild, moderate and severe VADs were found to be independently associated with cerebrovascular events [(OR: 2.73; 95% CI: 1.12-6.65; p = 0.027), (OR: 4.20; 95% CI: 1.86-9.45; p = 0.001) and (OR: 5.10; 95% CI: 2.14-12.17; p < 0.001) respectively].

Conclusions

Our study suggests that among Caucasian Sicilian subjects there are clear cut-off points of VAI able to identify a VAD strongly associated with cardiometabolic risk.

【 授权许可】

   
2011 Amato et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Beckley ET: New ADA initiative moves beyond 'metabolic syndrome'. 'Cardiometabolic risk' proposed as umbrella term for diabetes risk factors. DOC News 2006, 3:1-3.
• [2]Eckel RH, Kahn R, Robertson RM, Rizza RA: Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006, 113:2943-2946.
• [3]Lemieux I: Energy partitioning in gluteal-femoral fat: does the metabolic fate of triglycerides affect coronary heart disease risk? Arterioscler Thromb Vasc Biol 2004, 24:795-797.
• [4]Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ: Waist circumference and abdominal saggital diameter: best simple anthropometric indices of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994, 73:460-468.
• [5]Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després JP: Visceral obesity and the heart. Int J Biochem Cell Biol 2008, 40:821-826.
• [6]Taksali SE, Caprio S, Dziura J, Dufour S, Calí AM, Goodman TR, Papademetris X, Burgert TS, Pierpont BM, Savoye M, Shaw M, Seyal AA, Weiss R: High Visceral and Low Abdominal Subcutaneous Fat Stores in the Obese Adolescent: A Determinant of an Adverse Metabolic Phenotype. Diabetes 2008, 57:367-371.
• [7]Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH: Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab 2000, 278:E941-948.
• [8]Despres JP: Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006, 38:52-63.
• [9]Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
• [10]Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study Group: Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010, 33:920-922.
• [11]Bozorgmanesh M, Hadaegh F, Azizi F: Predictive performance of the visceral adiposity index for a visceral adiposity-related risk: type 2 diabetes. Lipids Health Dis 2011, 10:88. BioMed Central Full Text
• [12]Petta S, Amato M, Cabibi D, Cammà C, Di Marco V, Giordano C, Galluzzo A, Craxì A: Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 2010, 52:1543-1552.
• [13]Amato MC, Verghi M, Galluzzo A, Giordano C: The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Hum Reprod 2011, 26:1486-1494.
• [14]Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197.
• [15]European Society of Hypertension-European Society of Cardiology: Guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053.
• [16]Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
• [17]Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
• [18]Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D'Agostino RB Sr, O'Donnell CJ: Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007, 116:39-48.
• [19]Taksali SE, Caprio S, Dziura J, Dufour S, Calí AM, Goodman TR, Papademetris X, Burgert TS, Pierpont BM, Savoye M, Shaw M, Seyal AA, Weiss R: High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes 2008, 57:367-371.
• [20]Porter SA, Massaro JM, Hoffmann U, Vasan RS, O'Donnel CJ, Fox CS: Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care 2009, 32:1068-1075.
• [21]Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després JP: Visceral obesity and the heart. Int J Biochem Cell Biol 2008, 40:821-836.
• [22]Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH: Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab 2000, 278:E941-948.
• [23]Despres JP: Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006, 38:52-63.
• [24]Reaven GM: The individual components of the metabolic syndrome: is there a raison d'etre? J Am Coll Nutr 2007, 26:191-195.
• [25]Klein BE, Klein R, Lee KE: Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 2002, 25:1790-1794.
• [26]Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Després JP: Sex differences in the relation of visceral adipose tissue accumulation to total body fatness. Am J Clin Nutr 1993, 58:463-467.
• [27]Unger RH, Scherer PE: Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 2010, 21:345-352.